Warfarin or low-molecular-weight heparin therapy does not prolong pig-to-primate cardiac xenograft function

American Journal of Transplantation

Volumn 5, Issue 5, 2005, Pages 1011-1020

  Byrne, Guerard W ^a   Schirmer, Johannes M ^a   Fass, David N ^a   Teotia, Sumeet S ^a   Kremers, Walter K ^a   Xu, Hui ^a   Naziruddin, Bashoo ^a   Tazelaar, Henry D ^a   Logan, John S ^a   McGregor, Christopher G A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Antibody; Anticoagulation; Cardiac; Non Gal; Thrombosis; Xenotransplantation

Indexed keywords

ALPHA GALACTOSYL POLYETHYLENE GLYCOL CONJUGATE; BLOOD CLOTTING FACTOR 10A; CD20 ANTIBODY; CYCLOPHOSPHAMIDE; DEXAMETHASONE; ENOXAPARIN; IMMUNOSUPPRESSIVE AGENT; LOW MOLECULAR WEIGHT HEPARIN; MEMBRANE COFACTOR PROTEIN; RAPAMYCIN; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; WARFARIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ARTICLE; BABOON; CARDIAC GRAFT REJECTION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; GRAFT SURVIVAL; HEART FUNCTION; HEART GRAFT; HEART MUSCLE ISCHEMIA; HEART TRANSPLANTATION; HISTOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; INTERNATIONAL NORMALIZED RATIO; NONHUMAN; ORGAN DONOR; PRIMATE; PRIORITY JOURNAL; PROTHROMBIN TIME; SWINE; THROMBOCYTE; THROMBOSIS; TREATMENT OUTCOME; XENOTRANSPLANTATION;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTICOAGULANTS; ANTIGENS, CD; ANTIGENS, CD46; FACTOR XA; HEART TRANSPLANTATION; HEPARIN, LOW-MOLECULAR-WEIGHT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENTS; INTERNATIONAL NORMALIZED RATIO; ISCHEMIA; MEMBRANE GLYCOPROTEINS; MICROCIRCULATION; MYOCARDIUM; PAPIO; PRIMATES; PROTHROMBIN; SIROLIMUS; SWINE; TACROLIMUS; THROMBOSIS; TIME FACTORS; TRANSPLANTATION, HETEROLOGOUS; TREATMENT OUTCOME; VITAMIN K; WARFARIN;

EID: 20244380021     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2005.00792.x     Document Type: Article

References (43)

1. Lin SS, Kooyman DL, Daniels LJ et al. The role of natural anti-Gal α1-3Gal antibodies in hyperacute rejection of pig-to-baboon cardiac xenotransplants. Transplant Immunol 1997; 5: 212-218.
2. Kozlowski T, Shimizu A, Lambrigts D et al. Porcine kidney and heart transplantation in baboons undergoing a tolerance induction regimen and antibody adsorption. Transplantation 1999; 67: 18-30.
3. Leventhal JR, Dalmasso AP, Cromwell JW et al. Prolongation of cardiac xenograft survival by depletion of complement. Transplantation 1993; 55: 857-866.
4. Pruitt SK, Kirk AD, Bollinger RR et al. The effects of soluble complement receptor type 1 on hyperacute rejection of porcine xenografts. Transplantation 1994; 57: 363-370.
5. Kobayashi T, Taniguchi S, Neethling FA et al. Delayed xenograft rejection of pig-to-baboon cardiac transplants after cobra venom factor therapy. Transplantation 1997; 64: 1255-1261.
6. Salerno CT, Kulick DM, Yeh CG et al. A soluble chimeric inhibitor of C3 and C5 convertases, complement activation blocker-2, prolongs graft survival in pig-to-rhesus monkey heart transplantation. Xenotransplantation 2002; 9: 125-134.
7. McCurry KR, Kooyman DL, Alvarado CG et al. Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury. Nature Med 1995; 1: 423-427.
8. Byrne GW, McCurry KR, Martin MJ et al. Transgenic pigs expressing human CD59 and decay-accelerating factor produce an intrinsic barrier to complement-mediated damage. Transplantation 1997; 63: 149-155.
9. Cozzi E, Tucker AW, Langford GA et al. Characterization of pigs transgenic for human decay-accelerating factor. Transplantation 1997; 64: 1383-1392.
10. Lin SS, Weidner BC, Byrne GW et al. The role of antibodies in acute vascular rejection of pig-to-baboon cardiac transplants. J Clin Invest 1998; 101: 1745-1756.
11. Bach FH, Winkler H, Ferran C, Hancock WW, Robson SC. Delayed xenograft rejection. Immunol Today 1996; 17: 379-384.
12. Platt JL, Lin SS, McGregor CGA. Acute vascular rejection. Xenotransplantation 1998; 5: 169-175.
13. Xu H, Sharma A, Chen L et al. The structure of anti-Gal immunoglobulin genes in naive and stimulated Gal knockout mice. Transplantation 2001; 72: 1817-1825.
14. Xu H, Yin D, Naziruddin B et al. The in vitro and in vivo effects of anti-galactose antibodies on endothelial cell activation and xenograft rejection. J Immunol 2003; 170: 1531-1539.
15. Palmetshofer A, Galili U, Dalmasso AP, Robson SC, Bach FH. [alpha]-Galactosyl epitope-mediated activation of porcine aortic endothelial cells: Type I activation. Transplantation 1998; 65: 844-853.
16. Yin D, Zeng H, Ma L et al. Cutting Edge: NK cells mediate IgG1-dependent hyperacute rejection of xenografts. J Immunol 2004; 172: 7235-7238.
17. Platt JL, Vercellotti GM, Lindman BJ et al. Release of heparan sulfate from endothelial cells. J Exp Med 1990; 171: 1363-1368.
18. Mazzucato M, DeMarco L, Pradella P, Masotti A. Pareti FI. Porcine von Willebrand factor binding to human platelet GPIb induces transmembrane calcium influx. Thromb Haemost 1996; 75: 655-660.
19. Kopp CW, Siegel JB, Hancock WW et al. Effect of porcine endothelial tissue factor pathway inhibitor on human coagulation factors. Transplantation 1997; 63: 749-758.
20. Siegel JB, Grey ST, Lesnikoski BA et al. Xenogeneic endothelial cells activate human prothrombin. Transplantation 1997; 64: 888-896.
21. Cowan PJ, Aminian A, Barlow H et al. Renal xenografts from triple-transgenic pigs are not hyperacutely rejected but cause coagulopathy in non-immunosuppressed baboons. Transplantation 2000; 69: 2504-2515.
22. Cowan PJ, Aminian A, Barlow H et al. Protective effects of recombinant human antithrombin III in pig-to-primate renal xenotransplantation. Am J Transplant 2002; 2: 520-525.
23. Buhler L, Basker M, Alwayn IPJ et al. Coagulation and thrombotic disorders associated with pig organ and hematopoietic cell transplantation in nonhuman primates. Transplantation 2000; 70: 1323-1331.
24. Alwayn IP, Buhler L, Appel JZ, III et al. Mechanisms of thrombotic microangiopathy following xenogeneic hematopoietic progenitor cell transplantation. Transplantation 2001; 71: 1601-1609.
25. Vial CM, Ostlie DJ, Bhatti FNK et al. Life supporting function for over one month of a transgenic porcine heart in a baboon. J Heart Lung Transplant 2000; 19: 224-229.
26. Waterworth PD, Dunning J, Tolan M et al. Life-supporting pig-to-baboon heart xenotransplantation. J Heart Lung Transplant 1998; 17: 1201-1207.
27. Goddard MJ, Dunning JJ, Horsley J et al. Histopathology of cardiac xenograft rejection in the pig-to-baboon model. J Heart Lung Transplant 2002; 21: 474-484.
28. Diamond LE, Quinn CM, Martin MJ et al. A human CD46 transgenic pig model system for the study of discordant xenotransplantation. Transplantation 2001; 71: 132-142.
29. Schuurman HJ, Pino-Chavez G, Phillips MJ et al. Incidence of hyperacute rejection in pig-to-primate transplantation using organs from hDAF-transgenic donors. Transplantation 2002; 73: 1146-1151.
30. Cozzi E, Bhatti F, Schmoeckel M et al. Long-term survival of non-human primates receiving life-supporting transgenic porcine kidney xenografts. Transplantation 2000; 70: 15-21.
31. Kuwaki K, Knosalla C, Dor FJMF et al. Suppression of natural and elicited antibodies in pig-to-baboon heart transplantation using a human anti-human CD154 mAb-based regimen. Am J Transplant 2004; 4: 363-372.
32. Schirmer JM, Pass DN, Byrne GW et al. Effective antiplatelet therapy does not prolong transgenic pig to baboon cardiac xenograft survival. Xenotransplantation 2004; 11: 436-443.
33. Adams DH, Chen RH, Kadner A, Naficy S. Technique for heterotopic pig heart xenotransplantation in primates. Ann Thorac Surg 1999; 68: 265-268.
34. Byrne GW, Schwarz A, Fesi JR et al. Evaluation of different alpha-galactosyl glycoconjugates for use in xenotransplantation. Bioconjug Chem 2002; 13: 571-581.
35. Neethling FA, Cooper DKC. Serum cytotoxicity to pig cells and anti-αgal antibody level and specificity in humans and baboons. Transplantation 1999; 67: 658-665.
36. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol 1983; 1: 710-719.
37. Isermann B, Hendrickson SB, Hutley K, Wing M, Weiler H. Tissue-restricted expression of thrombomodulin in the placenta rescues thrombomodulin-deficient mice from early lethality and reveals a secondary developmental block. Development 2001; 128: 827-838.
38. Eitzman DT, Westrick RJ, Bi X et al. Lethal perinatal thrombosis in mice resulting from the interaction of tissue factor pathway inhibitor deficiency and factor V Leiden. Circulation 2002; 105: 2139-2142.
39. Diamond LE, Byrne GW, Schwarz A et al. Analysis of the control of the anti-Gal immune response in a non-human primate by galactose alpha-1-3 galactose trisaccharide-polyethylene glycol conjugate. Transplantation 2002; 73: 1780-1787.
40. Gollackner B, Knosalla C, Houser S et al. Pig kidney transplantation in baboons treated intravenously with a bovine serum albumin-Galalpha1-3Gal conjugate. Xenotransplantation 2003; 10: 606-614.
41. Domenech N, Diaz T, Moscoso I et al. Elicited non-anti-alphaGAL antibodies may cause acute humoral rejection of hDAF pig organs transplanted in baboons. Transplant Proc 2003; 35: 2049-2050.
42. Buhler L, Xu Y, Li W, Zhu A, Cooper DK. An investigation of the specificity of induced anti-pig antibodies in baboons. Xenotransplantation 2003; 10: 88-93.
43. Gollackner B, Goh SK, Qawi I et al. Acute vascular rejection of xenografts: roles of natural and elicited xenoreactive antibodies in activation of vascular endothelial cells and induction of procoagulant activity. Transplantation 2004; 77: 1735-1741.